HOW WE'RE MAKING A DIFFERENCE
Austen's Army Foundation has committed funds to the following research projects focused on rhabdomyosarcoma:
In an unprecedented international partnership with ten families whose lives have been touched by childhood cancer, a potentially groundbreaking drug development project is underway at the Children’s Cancer Therapy Development Institute () in Portland, Oregon.
The cancer being studied is rhabdomyosarcoma, a type of soft tissue malignancy that emerges from and/or shares properties with muscle. The group will be validating one of the key compounds from a screen of 640,000 compounds.
Dr. Robert Schnepp is conducting research through Children's Healthcare of Atlanta focused on examining an epigenetic protein (BMI1) found in alveolar rhabdomyosarcoma that could possibly be a driver in the formation of the diseases.
The aim of the research is to understand how BMI1 shapes rhabdomyosarcoma aggression and whether inhibiting this protein can provide novel and better treatment options. Overall, the goal is to leverage the findings generated from our studies to improve therapeutic options for people diagnosed with these malignancies.